Compare IDEXX Laboratories, Inc. (IDXX) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Marvell Technology Inc — how do they compare? IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B), while Marvell Technology Inc trades at $274.99 (market cap $246.84B). The key difference: Marvell Technology Inc is far larger — about 6.1× IDEXX Laboratories, Inc.'s market cap, and Marvell Technology Inc pays a 0.09% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Marvell Technology Inc for 42 Days on average.
| IDXX | MRVL | |
|---|---|---|
Market Cap | $40.43B | $246.84B |
Volume | 692,164 | 29,003,830 |
Sector | Health | Technology |
52-Week High | $766.68 | $316.43 |
52-Week Low | $504.70 | $73.73 |
Typical Hold Time | 46 Days | 42 Days |
Enterprise Value | $41.32B | $248.19B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Marvell Technology (MRVL) trades at $271.49, down 4.63% today but maintains strong momentum with 210% year-to-date gains. The stock shows bullish technical signals with support at $267 and resistance at $282. Fundamentally, MRVL reported three consecutive earnings beats and projects explosive growth, with fiscal 2028 revenue guidance raised to $18 billion. Analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $327.86 consensus target.
MRVL presents compelling growth prospects driven by AI chip demand and hyperscaler partnerships, particularly the $120 billion Google deal. However, elevated valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) warrant caution. The stock's 210% surge this year increases volatility risk, though strong institutional support and custom silicon expansion provide long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
